Fig 1: XQ-2d-His-SH2 CM-(Arg)9 conjugate exhibited potent antitumor efficacy in vitro. (A) Effects of XQ-2d-His-SH2 CM-(Arg)9 on the proliferation of BxPC-3 and PANC-1 cells. Cells were treated with His-alone, (Arg)9, His-SH2 CM, His-(Arg)9, XQ-2d, XQ-2d-His-SH2 CM, XQ-2d-His-SH2 CM-(Arg)9, and His-SH2 CM-(Arg)9 at 100 nM for 3 h. Cell viability was measured by MTT assays. (B) Representative images of colony formation assay showing colonies formed by cells incubated with different treatments. (C) Bar graph depicting the change in the number of cell colonies. (D) Wound healing assays were monitored at 0 and 16 h in PANC-1 or BxPC-3 cells with different treatments. Scale bar: 100 µm. (E) Bar graph depicting the change of migration rate. (F) Representative images and results of transwell assays of PANC-1 or BxPC-3 cells with different treatments. Scale bar: 20 µm. (G) Bar graph depicting the change in the number of invasion cells. (H) The expressions of N-cadherin, E-cadherin, Vimentin, CK8, TWIST1, and Snail1 were examined by western blot. Cells were stimulated with XQ-2d-His-SH2 CM-(Arg)9 and other negative controls at 100 nM for 3 h. All images shown are representative of at least three independent experiments (*P < 0.05)